Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSkinbiotherap. Regulatory News (SBTX)

Share Price Information for Skinbiotherap. (SBTX)

Share Price is delayed by 15 minutes
Get Live Data
12.25    1.00 (8.89%)
Bid:
12.00
Ask:
12.50
Spread: 0.50 (4.167%)
Market Cap: £31.75m
SBTX Live PriceLast checked at - London Stock Exchange

Intraday Skinbiotherap. Share Chart

Holding(s) in Company

30 Jan 2023 16:28

RNS Number : 3057O
SkinBioTherapeutics PLC
30 January 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights areattachedii:

 

SKINBIOTHERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer(please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification(please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Optibiotix Health Plc

City and country of registered office (if applicable)

UK

4. Full name of shareholder(s)(if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

05/01/2023

6. Date on which issuer notified (DD/MM/YYYY):

30/01/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial instru- ments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of is- suervii

Resulting situation on the date on which

threshold was crossed or reached

 

18.71%

 

173,138,854

Position of previous notification (if applicable)

 

20.67%

 

1

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

32,402,206

18.71%

SUBTOTAL 8. A

32,402,206

18.71%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial in- strument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Pe-

riod xi

Physical or cash

settlementxii

Number of voting rights

 

% of voting rights

SUBTOTAL

8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv

(please add additional rows as necessary)

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

30/01/2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBMMFTMTTJBAJ
Date   Source Headline
25th Jun 202612:00 pmRNSDirectorate change
23rd Jun 202612:03 pmRNSNotice of Investor Presentation
8th Jun 20267:30 amRNSRestoration - SkinBioTherapeutics PLC
8th Jun 20267:00 amRNSHalf-year Results (HY26) and Restated FY25 Results
28th May 20267:00 amRNSUpdate on Investigation, Interims and Auditors
12th May 202610:13 amRNSHolding(s) in Company
5th May 20262:30 pmRNSHolding(s) in Company
29th Apr 20262:30 pmRNSUpdate on the FRP Investigation
1st Apr 202610:30 amRNSHolding(s) in Company
1st Apr 20267:30 amRNSSuspension - Skinbiotherapeutics plc
1st Apr 20267:00 amRNSStatement re. Suspension
20th Mar 202611:30 amRNSUpdate On Board Investigation and Interims Date
13th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20267:00 amRNSHolding(s) in Company
9th Mar 20267:00 amRNSAppointment of the Interim CEO to the Board
2nd Mar 20267:00 amRNSAppointment of Interim CEO
20th Feb 20267:00 amRNSIndependent Investigation Appointment
16th Feb 20267:00 amRNSUpdate on Board Investigation
13th Feb 20267:00 amRNSResignation of CEO
12th Feb 202611:00 amRNSHolding(s) in Company
11th Feb 20267:00 amRNSIssue of Equity and Total Voting Rights
29th Jan 20267:00 amRNSHolding(s) in Company
22nd Jan 20269:00 amRNSTotal Voting Rights
20th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 20267:00 amRNSIssue of Equity and Total Voting Rights
15th Jan 20263:21 pmRNSHolding(s) in Company
7th Jan 202611:00 amRNSHolding(s) in Company
5th Jan 20267:00 amRNSDirectorate change
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
29th Dec 20252:00 pmRNSResult of AGM
29th Dec 20252:00 pmRNSResult of AGM
29th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSReconfirmation of Market Guidance and AGM Q&A
8th Dec 20252:31 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSPosting of Annual Report and AGM Notice
5th Dec 20257:00 amRNSFinal Results
26th Nov 20257:00 amRNSHolding(s) in Company
19th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20253:41 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSDirectorate Change
13th Oct 20253:31 pmRNSHolding(s) in Company
13th Oct 20253:30 pmRNSHolding(s) in Company
6th Oct 20257:00 amRNSSuperdrug first phase of store locations
1st Oct 20254:30 pmRNSHolding(s) in Company
14th Aug 20257:00 amRNSFY Trading Update
30th Jun 20257:00 amRNSCroda Commercial Launch Progressing as Expected
27th Jun 20257:00 amRNSNotice of IMC Shareholder Presentation
25th Jun 202511:28 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.